Literature DB >> 27718152

Differential BMI1, TWIST1, SNAI2 mRNA expression pattern correlation with malignancy type in a spectrum of common cutaneous malignancies: basal cell carcinoma, squamous cell carcinoma, and melanoma.

F Vand-Rajabpour1, N Sadeghipour1, S Saee-Rad2, H Fathi3,4, P Noormohammadpour4, M Yaseri5, K K Hesari4, Z Bagherpour1, M Tabrizi6.   

Abstract

PURPOSE: Melanoma, squamous cell carcinoma (SCC), and basal cell carcinoma (BCC) can be used as a unique model to identify molecular mechanisms to distinguish rarely metastatic (BCC), often metastatic (SCC) and most metastatic (melanoma) cancer. It is known that epithelial-mesenchymal transition and stemness transcription factors (TWIST1, SNAI2/SLUG, and BMI1) play an important role in metastasis and their dysregulation has been demonstrated in metastatic cancers. We hypothesized that this spectrum of cutaneous cancers (BCC, SCC, and melanoma) would be a unique cancer model system to elucidate steps toward cancer invasion and metastasis.
METHODS: We evaluated the mRNA expression level of BMI1, TWIST1, and SNAI2/SLUG and studied clinicopathological features in 170 skin cancers along with normal tissue samples.
RESULTS: We demonstrate downregulation of BMI1 mRNA expression in BCC samples compared with controls (p = 0.0001), SCC (p = 0.001), and melanoma (p = 0.0001) samples. Downregulation of TWIST1 mRNA expression is seen in only BCC samples compared with controls (p = 0.031). High SNAI2 mRNA expression is represented in melanoma samples compared with controls (p = 0.022) and SCC samples (p = 0.031). High mRNA expression of TWIST1 is seen in patients with positive history of cancers. Extremely low mRNA expression of BMI1 is detected in patients with positive history of cancers other than skin cancer.
CONCLUSIONS: These findings provide support for the hypothesis that the spectrum of cutaneous cancers could be better understood as a series of gene dosage-dependent entities with distinct molecular events. Oncogene-induced senescence, mechanism of which is still unclear, could be one explanation for these results.

Entities:  

Keywords:  BMI1; Epithelial–mesenchymal transition; Metastasis; SNAI2/SLUG; Stemness; TWIST1

Mesh:

Substances:

Year:  2016        PMID: 27718152     DOI: 10.1007/s12094-016-1555-4

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  33 in total

Review 1.  Bmi1, stem cells, and senescence regulation.

Authors:  In-Kyung Park; Sean J Morrison; Michael F Clarke
Journal:  J Clin Invest       Date:  2004-01       Impact factor: 14.808

2.  Twist1 as a possible biomarker for metastatic basal cell carcinoma.

Authors:  Yuta Majima; Satoshi Hirakawa; Yukiko Kito; Hiroki Suzuki; Masayo Koide; Hidekazu Fukamizu; Yoshiki Tokura
Journal:  Acta Derm Venereol       Date:  2012-11       Impact factor: 4.437

3.  Slug expression during melanoma progression.

Authors:  Stephanie H Shirley; Victoria R Greene; Lyn M Duncan; Carlos A Torres Cabala; Elizabeth A Grimm; Donna F Kusewitt
Journal:  Am J Pathol       Date:  2012-04-13       Impact factor: 4.307

4.  Expression of RUNX3 in skin cancers.

Authors:  J H Lee; J-K Pyon; D W Kim; S H Lee; H S Nam; S G Kang; C H Kim; Y J Lee; J S Chun; M K Cho
Journal:  Clin Exp Dermatol       Date:  2011-05-30       Impact factor: 3.470

Review 5.  Normal and disease-related biological functions of Twist1 and underlying molecular mechanisms.

Authors:  Qian Qin; Young Xu; Tao He; Chunlin Qin; Jianming Xu
Journal:  Cell Res       Date:  2011-08-30       Impact factor: 25.617

6.  p16 gene expression in basal cell carcinoma.

Authors:  Sima Ataollahi Eshkoor; Patimah Ismail; Sabariah Abdul Rahman; Soraya Ataollahi Oshkour
Journal:  Arch Med Res       Date:  2008-10       Impact factor: 2.235

Review 7.  Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits.

Authors:  Kornelia Polyak; Robert A Weinberg
Journal:  Nat Rev Cancer       Date:  2009-03-05       Impact factor: 60.716

8.  BMI1 and TWIST1 downregulated mRNA expression in basal cell carcinoma.

Authors:  Fatemeh Vand Rajabpour; Reza Raoofian; Leila Youssefian; Hassan Vahidnezhad; Mostafa Mirshams Shahshahani; Hamidreza Fathi; Pedram Noormohammadpour; Kambiz Kamyab Hesari; Morteza Hashemzadeh-Chaleshtori; Mina Tabrizi
Journal:  Asian Pac J Cancer Prev       Date:  2014

9.  Loss of BMI-1 expression is associated with clinical progress of malignant melanoma.

Authors:  Ingeborg M Bachmann; Hanne E Puntervoll; Arie P Otte; Lars A Akslen
Journal:  Mod Pathol       Date:  2008-02-08       Impact factor: 7.842

10.  p38 MAPK-Mediated Bmi-1 down-regulation and defective proliferation in ATM-deficient neural stem cells can be restored by Akt activation.

Authors:  Jeesun Kim; Jeon Hwangbo; Paul K Y Wong
Journal:  PLoS One       Date:  2011-01-28       Impact factor: 3.240

View more
  4 in total

1.  Decreased Sox2 Messenger RNA Expression in Basal Cell Carcinoma.

Authors:  Reza Ahmadi-Beni; Fatemeh Vand-Rajabpour; Mohamadreza Ahmadifard; Maryam Daneshpazhooh; Pedram Noormohammadpour; Javad Rahmati; Kambiz Kamyab Hesari; Mehdi Yaseri; Mina Tabrizi
Journal:  Indian J Dermatol       Date:  2020 May-Jun       Impact factor: 1.494

Review 2.  The Contributions of Cancer-Testis and Developmental Genes to the Pathogenesis of Keratinocyte Carcinomas.

Authors:  Brandon Ramchatesingh; Jennifer Gantchev; Amelia Martínez Villarreal; Raman Preet Kaur Gill; Marine Lambert; Sriraam Sivachandran; Philippe Lefrançois; Ivan V Litvinov
Journal:  Cancers (Basel)       Date:  2022-07-26       Impact factor: 6.575

3.  IL-17A promotes cell migration and invasion of glioblastoma cells via activation of PI3K/AKT signalling pathway.

Authors:  Qianqian Zheng; Shuo Diao; Qi Wang; Chen Zhu; Xun Sun; Bo Yin; Xinwen Zhang; Xin Meng; Biao Wang
Journal:  J Cell Mol Med       Date:  2018-10-24       Impact factor: 5.310

4.  Whole‑genome identification and systematic analysis of lncRNA‑mRNA co‑expression profiles in patients with cutaneous basal cell carcinoma.

Authors:  Jiaan Zhang; Xuyue Zhou; Chenpu Zhu; Yu Hu; Rong Li; Shuang Jin; Dan Huang; Mei Ju; Kun Chen; Chao Luan
Journal:  Mol Med Rep       Date:  2021-07-19       Impact factor: 2.952

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.